Tag: HEOR
EU HTA Is Changing European Market Access: Why Early Evidence Planning Is Now Essential
EU HTA Is Changing European Market Access: Why Early Evidence Planning Is Now Essential The European pharmaceutical industry is entering a new era. With the implementation of the European Union Health Technology Assessment (EU HTA) Regulation, companies must rethink how they generate clinical evidence, align cross-functional teams, and prepare for successful market access across Europe.…
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission How pre-submission evidence reviews are becoming the next competitive advantage for pharmaceutical and biotech companies in Europe. The pharmaceutical industry has entered a new era of evidence generation. For years, achieving regulatory approval was considered the biggest milestone on the path to…
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Pharma’s Competitive Advantage Under EU HTA
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Becoming Pharma’s Competitive Advantage Under EU HTA How cross-functional collaboration, Real-World Evidence, AI, and early planning are reshaping successful market access strategies across Europe. The European pharmaceutical landscape is changing rapidly. Over the past year, discussions around the EU Health Technology Assessment (HTA) Regulation…
EU HTA Joint Clinical Assessments: 7 Critical Pharma Mistakes
EU HTA Joint Clinical Assessments (JCA): The 7 Critical Mistakes Pharma Companies Must Avoid Before Their First Submission The European healthcare landscape is undergoing one of the most significant transformations in decades. With the implementation of the European Union Health Technology Assessment (EU HTA) Regulation and the introduction of Joint Clinical Assessments (JCA), pharmaceutical and…
DARWIN EU 2.0 & JCA PICO Strategy: Streamlining Multi-State RWE
Mastering DARWIN EU 2.0 Interoperability for JCA Compliance: The Technical Blueprint for Multi-State Real-World Evidence The European market access landscape is undergoing its most profound structural disruption since the centralization of regulatory approvals. The rollout of the European Union Health Technology Assessment (EU-HTA) regulation has effectively shifted the goalposts for pharmaceutical manufacturers. No longer can…
Why Global Health Agencies Are Demanding RWE in 2025
Why Global Health Agencies Are Demanding Real-World Evidence in 2025 And What It Means for Market Access In 2025, healthcare is no longer defined by clinical trial results alone. Across the globe, regulatory bodies and health technology assessment (HTA) agencies are making one thing crystal clear: Real-World Evidence (RWE) is now a non-negotiable requirement for…
